Future oncology最新文献

{"title":"Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.","authors":"Jonathan Krell, Danielle Shaw, John McGrane, Andreas Hartkopf, Ana Herrero, Cheng Yeoh, Maria Masvidal, Francesco Raspagliesi, Whitney York, Jeanne M Schilder, Barbara Mascialino, Eleanor McDermott, Linda Kalilani, Lars Hanker","doi":"10.1080/14796694.2024.2402217","DOIUrl":"https://doi.org/10.1080/14796694.2024.2402217","url":null,"abstract":"<p><p><b>Aim:</b> The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer.<b>Patients & methods:</b> Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known <i>BRCA mutation</i>, interval debulking surgery or no surgery, or visible residual disease.<b>Results:</b> Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS.<b>Conclusion:</b> Risk profiles should be carefully considered when planning clinical care.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence from Europe on implementation, participation and performance of self-collection for cervical cancer screening.","authors":"Susie Huntington, Jennifer S Smith, Dave Nuttall, Andrea Polokaova, Phoebe Marson Smith, Charlotte Hamlyn-Williams, Elisabeth Adams","doi":"10.1080/14796694.2024.2409625","DOIUrl":"https://doi.org/10.1080/14796694.2024.2409625","url":null,"abstract":"<p><p>Cervical cancer screening programs reduce the number of cervical cancer cases and deaths, but the success of any screening program is dependent on high participant uptake and coverage and many European countries are observing declining cervical cancer screening coverage to below national targets. Self-collection of vaginal samples for human papillomavirus testing, also termed self-sampling, is one strategy which is being introduced to try to increase screening coverage by removing barriers to participation and it has attracted growing interest and support globally. Informed by peer-reviewed and gray literature, this narrative review starts with a case study from the Netherlands and outlines the self-collection landscape in Europe within the themes of program implementation and relative test performance. It highlights some of the current evidence gaps needed to inform policy decisions on the use of self-collection within screening programs.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests.","authors":"Chi Van Thien Nguyen, Thi Hue Hanh Nguyen, Dac Ho Vo, Thi Tuong Vi Van, Giang Thi Huong Nguyen, Trung Hieu Tran, Trong Hieu Nguyen, Le Anh Khoa Huynh, Thanh Dat Nguyen, Nhat-Huy Tran, Thi Minh Thi Ha, Phan Tuong Quynh Le, Xuan Long Truong, Hong-Dang Luu Nguyen, Uyen Vu Tran, Thanh Quang Hoang, Viet Binh Nguyen, Van Cuong Le, Xuan Chung Nguyen, Thi Minh Phuong Nguyen, Van Hung Nguyen, Nu Thien Nhat Tran, Thi Ngoc Quynh Dang, Manh Hoang Tran, Phuc Nguyen Nguyen, Thi Huyen Dao, Huu Tam Phuc Nguyen, Nhat-Thang Tran, Thi Van Phan, Duy Sinh Nguyen, Hung Sang Tang, Hoa Giang, Minh-Duy Phan, Hoai-Nghia Nguyen, Le Son Tran","doi":"10.1080/14796694.2024.2413266","DOIUrl":"https://doi.org/10.1080/14796694.2024.2413266","url":null,"abstract":"<p><p><b>Aim:</b> Cancers lacking standard screening (LSS) options account for approximately 70% of cancer-related deaths due to late-stage diagnosis. Circulating tumor DNA (ctDNA) is a promising biomarker for multi-cancer early detection. We previously developed SPOT-MAS, a multimodal ctDNA-based assay analyzing methylation and fragmentomic profiles, effective in detecting common cancers (breast, colorectal, liver, lung and gastric). This study extends the analysis to five LSS cancers: endometrial, esophageal, head and neck, ovarian and pancreatic.<b>Methods:</b> SPOT-MAS was applied to profile cfDNA methylation and fragmentomic patterns in 739 healthy individuals and 135 LSS cancer patients.<b>Results:</b> We identified 347 differentially methylated regions and observed genome-wide hypomethylation across all five LSS cancers. Esophageal and head and neck cancers showed an enrichment of short cfDNA fragments (<150 bp). Eleven 4-mer end motifs were consistently altered in cfDNA fragments across all LSS cancers. Many significant signatures were consistent with previous observations in common cancers. Notably, SPOT-MAS achieved 96.2% specificity and 74.8% overall sensitivity, with a lower sensitivity of 60.7% in early-stage cancers.<b>Conclusion:</b> This proof-of-concept study demonstrates that SPOT-MAS a non-invasive test trained on five common cancer types, could detect a number of LSS cancer cases, potentially complementing existing screening programs.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.","authors":"Xiaoping Zhang, Li Yang, Minyi Zhu, Xiaotian Zhao, Yao Xiao, Jiaohui Pang, Liuqing Zhu, Qiuxiang Ou, Hai-Wen Ni, Jingyan Xu","doi":"10.1080/14796694.2024.2402209","DOIUrl":"https://doi.org/10.1080/14796694.2024.2402209","url":null,"abstract":"<p><p><b>Aim:</b> Advances in circulating tumor DNA (ctDNA) analysis for diffuse large B-cell lymphoma (DLBCL) have prompted the evaluation of its utility in other non-Hodgkin lymphomas (NHLs), leading to significant insights into its potential applications.<b>Methods:</b> We retrospectively studied paired plasma and tissue/bone marrow biopsies of 203 non-DLBCL NHLs [87 follicular lymphomas (FL), 64 mantle cell lymphomas (MCL), 30 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL) and 22 marginal zone lymphomas (MZL)]. Genomic profiling was performed using a targeted next generation sequencing panel (Hemasalus^™). Longitudinal analyses were performed to explore plasma ctDNA utility in disease monitoring.<b>Results:</b> High plasma ctDNA detection rates were observed across NHL subtypes (FL: 88.5%, MCL: 90.6%, CLL/SLL: 100%, MZL: 68.2%), with high concordance of actionable mutations (FL: 87.4%, MCL: 93.8%, CLL/SLL: 93.3%, MZL: 81.8%) and multiple genetic aberrations exclusively identified in plasma. Particularly, <i>IGH-BCL2</i> and <i>IGH-CCND1</i> fusions were concordant between plasma and tumor biopsies in FLs (91.1%) and MCLs (91.3%), respectively. Longitudinal data demonstrated that ctDNA clearance correlated with complete response but ctDNA increases preceded radiological relapses.<b>Conclusion:</b> ctDNA exhibited high concordance with tumor biopsy in detecting genetic aberrations and demonstrated potential as a promising noninvasive approach to disease surveillance in non-DLBCL NHLs.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.","authors":"Andrew J Armstrong, Arun A Azad, Ciara Conduit, Gabriel P Haas, Christopher Bland, Ian D Davis","doi":"10.1080/14796694.2024.2408101","DOIUrl":"https://doi.org/10.1080/14796694.2024.2408101","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary includes information from the ARCHES and ENZAMET <b>follow-up studies</b>. Both studies looked at enzalutamide treatment for people with metastatic hormone-sensitive prostate cancer (known as mHSPC). In ARCHES, researchers compared the medications enzalutamide + androgen deprivation therapy (known as ADT) with <b>placebo</b> + ADT. In ENZAMET, researchers compared enzalutamide + ADT with <b>standard treatment</b> + ADT. Some people in ENZAMET also took enzalutamide with docetaxel (a <b>chemotherapy</b> treatment). In both studies, researchers wanted to find out if enzalutamide helps people with mHSPC live longer.</p><p><strong>What are the key takeaways?: </strong>In both studies, researchers found that people with mHSPC who took enzalutamide lived longer than people who did not. People who took enzalutamide also lived longer without their cancer getting worse. The results were mostly similar in groups of people dependingon when and where their cancer was found. Researchers did not find any new safety concerns.</p><p><strong>What were the main conclusions?: </strong>People with mHSPC may benefit from long-term treatment with enzalutamide + ADT. They may also benefit from taking enzalutamide with other treatments, like docetaxel. It may be better for people with mHSPC to have enzalutamide treatment before their cancer gets worse, rather than waiting. These people and their doctors should carefully consider the benefits and risks of each treatment to make a joint decision for treating mHSPC.<b>Clinical Trial Registration:</b> NCT02677896 (ARCHES), NCT02446405 (ENZAMET) (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysis.","authors":"Jia Qin Cai, Yi Ming Wang, Xinmiao Lin, Mumu Xie, Guifeng Zhang, Xiao Xia Wei, Hong Sun","doi":"10.1080/14796694.2024.2370239","DOIUrl":"https://doi.org/10.1080/14796694.2024.2370239","url":null,"abstract":"<p><p><b>Aim:</b> We conducted network meta-analysis to assess cardiovascular toxicity of anaplastic lymphoma kinase-tyrosine kinase inhibitors (<i>ALK</i>-TKIs).<b>Materials & methods:</b> Eleven articles involving 2855 patients and six interventions including crizotinib, alectinib, ceritinib, lorlatinib, brigatinib and chemotherapy were analyzed.<b>Results:</b> No significant difference was observed in overall cardiovascular risk among <i>ALK</i>-TKIs. Subgroup analysis showed that for cardiac toxicity, crizotinib and alectinib were more likely to cause myocardial rhythm abnormalities. Crizotinib and ceritinib had a higher risk of Q-T prolongation than chemotherapy. For vascular toxicity, crizotinib and ceritinib had a higher risk of thrombotic events than brigatinib. Crizotinib and lorlatinib were more likely to cause blood pressure abnormalities.<b>Conclusion:</b> Clinicians should carefully monitoring cardiovascular events when <i>ALK</i>-TKIs used in NSCLCs patients with baseline cardiovascular diseases.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.","authors":"Ehab L Atallah, Michael J Mauro, Koji Sasaki, Moshe Y Levy, Paul Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Jorge E Cortes","doi":"10.1080/14796694.2024.2402680","DOIUrl":"https://doi.org/10.1080/14796694.2024.2402680","url":null,"abstract":"<p><p>Up to 40% of newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) discontinue treatment by 5 years, primarily due to resistance or intolerance. Rates of resistance to second-line (2L) treatment are also high. Some patients with resistance respond with dose escalation of tyrosine kinase inhibitors (TKIs). Asciminib demonstrated safety and efficacy across a broad dosage range. ASC2ESCALATE is an ongoing, Phase II, multicenter, single-arm, dose-escalation study of asciminib in 2L and first-line treatment of CML-CP. The primary end point is major molecular response at 12 months in 2L. Secondary end points include molecular responses at and by scheduled time points, survival, and safety. ASC2ESCALATE is the first study investigating asciminib in CML-CP following failure of one prior TKI.<b>Clinical Trial Registration:</b> NCT05384587 (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/14796694.2024.2413743","DOIUrl":"https://doi.org/10.1080/14796694.2024.2413743","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1"},"PeriodicalIF":3.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial.","authors":"Nicholas M Bernthal, Sydney Stern, Jean-Yves Blay","doi":"10.1080/14796694.2024.2398893","DOIUrl":"https://doi.org/10.1080/14796694.2024.2398893","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This article presents a patient-friendly summary of the MOTION <b>phase 3 clinical trial</b> results, which were published in <i>The Lancet</i> in June 2024.The primary goal of the MOTION trial was to understand if treatment with a drug called vimseltinib shrank tumors more than a placebo in participants with symptomatic tenosynovial giant cell tumor, also known as TGCT, for which surgery was unlikely to provide benefit. A placebo is something that looks like the treatment being studied but does not contain any medicine.The MOTION trial compared the effects of vimseltinib versus a placebo using several different outcomes associated with TGCT. These outcomes included tumor size, active range of motion of the affected joint, and several patient-reported quality-of-life measures including physical function, stiffness, overall health, and pain.</p><p><strong>What were the main conclusions reported by the researchers?: </strong>The trial showed that more participants treated with vimseltinib experienced significant tumor shrinkage, as defined by a 30% or greater reduction in tumor size, compared with those receiving a placebo. Participants receiving vimseltinib had improved active range of motion, and they reported improved physical function, stiffness, overall health, and pain, regardless of the amount of tumor shrinkage, compared with participants receiving a placebo. Most side effects in participants treated with vimseltinib were not severe and were manageable.</p><p><strong>What are the key takeaways?: </strong>Vimseltinib was better at shrinking tumors and improving active range of motion, stiffness, pain, and other health measures than the placebo for participants with TGCT. Vimseltinib has the potential to become a new treatment option for patients with TGCT for whom surgery may not provide benefit.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the prognostic effectiveness of liver metastasis volume by volumetric measurement in colorectal cancer.","authors":"İlknur Deliktaş Onur, Pınar Özdemir Akdur, Elif Sertesen Çamöz, Nazan Çiledağ, Fatih Yıldız","doi":"10.1080/14796694.2024.2406221","DOIUrl":"https://doi.org/10.1080/14796694.2024.2406221","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the relationship between liver metastasis volume and survival in colorectal cancer patients using the volumetric measurement method.<b>Methods:</b> 114 colorectal cancer patients with isolated liver metastases were included in the study. Liver tumor volume, total liver volume were calculated from the patients images at the time of diagnosis. Vitrea 7.14 imaging software was used for liver volume analysis and volume analysis of each metastasis.<b>Results:</b> Median overall survival(OS) in the group with tumor volume <42 ml³ was 30.98 months In the group with tumor volume ≥42 ml³, median OS was 16.36 months (<i>p</i>: 0.001). In patients who underwent metastasectomy, the median OS in the group with a tumor volume <42 ml³ was 52.3 months, the median OS in the group with a tumor volume ≥42 ml³ was 22.2 months. In patients who did not undergo metastasectomy, the median OS in the <42 ml³ group was 20.23 months, the median OS in the ≥42 ml³ group was 15.63 months.<b>Conclusion:</b> In our study, we found that liver metastasis volume was prognostic for OS. It is argued that tumor volume measurement by volumetric measurement is a widely used method in the decision for metastasectomy in liver metastatic colorectal cancer patients.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}